{"id":557056,"date":"2021-08-10T19:34:01","date_gmt":"2021-08-10T19:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=557056"},"modified":"2021-08-10T19:34:01","modified_gmt":"2021-08-10T19:34:01","slug":"agerelated-macular-degeneration-amd-market-size-and-trends-analysis-clinical-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/agerelated-macular-degeneration-amd-market-size-and-trends-analysis-clinical-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast_557056.html","title":{"rendered":"Age-related Macular Degeneration (AMD) Market Size and Trends Analysis, Clinical Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Age-related Macular Degeneration (AMD) Market Size and Trends Analysis, Clinical Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Age-related Macular Degeneration (AMD) Market Size and Trends Analysis, Clinical Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Age-related Macular Degeneration (AMD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Age-related Macular Degeneration (AMD) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Age-related Macular Degeneration is a disease that damages the retina and affects a person&rsquo;s central vision due to which the images that used to be clear start appearing blurred, dark spots may appear, which get progressively bigger. AMD mainly affects a smaller area near the center of the retina, called the macula, which is needed for detailed tasking such as reading, driving, etc.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Age-related Macular Degeneration (AMD) Market Research Report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Age-related Macular Degeneration (AMD) market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Age-related Macular Degeneration (AMD) treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/age-related-macular-degeneration-amd-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Age-related Macular Degeneration (AMD) Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/75ccea5fb3191e89450a69d4eeeb1442.jpg\" alt=\"Age-related Macular Degeneration (AMD) Market \" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Age-related Macular Degeneration (AMD) Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report provides an in-depth analysis of <strong>Age-related Macular Degeneration (AMD) Market Size, Share, Trend, and Epidemiology Forecast<\/strong> till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report will help in developing business strategies by understanding the Age-related Macular Degeneration (AMD) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report covers the <strong>Age-related Macular Degeneration (AMD) current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in the seven major markets.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the Age-related Macular Degeneration (AMD) market in terms of market drivers &amp; barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Age-related Macular Degeneration (AMD) Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Age-related Macular Degeneration (AMD) market size and share<\/strong> by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Age-related Macular Degeneration (AMD) market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request for Sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Age-related Macular Degeneration (AMD) Therapeutics Market Assessment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Age-related Macular Degeneration (AMD) Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights about the historical and current <strong>Age-related Macular Degeneration (AMD) patient pool and forecasted trends<\/strong> for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Age-related Macular Degeneration (AMD) Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Age-related Macular Degeneration (AMD) market<\/strong> or expected to get launched in the market during the study period. The analysis covers Age-related Macular Degeneration (AMD) market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Age-related Macular Degeneration (AMD) Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies in the Age-related Macular Degeneration (AMD) Market includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ribomic USA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amgen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lineage Cell Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adverum Biotechnologies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kodiak Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Graybug Vision<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Age-related Macular Degeneration (AMD) Therapies covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GB-102<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KSI 301<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ADVM-022<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OpRegen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ABP 938<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RBM-007 Injectable Solution<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>And many more.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mechanisms of Action (MoA)<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Placenta growth factor inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vascular endothelial growth factor A inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Angiogenesis inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Colony-stimulating factor receptor antagonists<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vascular endothelial growth factors inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fibroblast growth factor inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cell replacements<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Age-related Macular Degeneration (AMD) Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Age-related Macular Degeneration (AMD) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Age-related Macular Degeneration (AMD) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Age-related Macular Degeneration (AMD) Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Age-related Macular Degeneration (AMD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Age-related Macular Degeneration (AMD) Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Age-related Macular Degeneration (AMD) Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Age-related Macular Degeneration (AMD) Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Age-related Macular Degeneration (AMD) Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Age-related Macular Degeneration (AMD) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Age-related Macular Degeneration (AMD) Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Age-related Macular Degeneration (AMD) Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Age-related Macular Degeneration (AMD) Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Age-related Macular Degeneration (AMD) Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Age-related Macular Degeneration (AMD) Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Age-related Macular Degeneration (AMD) Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/age-related-macular-degeneration-amd-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Age-related Macular Degeneration (AMD) Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Age-related Macular Degeneration (AMD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Age-related Macular Degeneration (AMD) market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-with-diabetes-market-forecast\">Dementia with Diabetes Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dementia with Diabetes market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><br \/><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=agerelated-macular-degeneration-amd-market-size-and-trends-analysis-clinical-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=agerelated-macular-degeneration-amd-market-size-and-trends-analysis-clinical-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Age-related Macular Degeneration (AMD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Age-related Macular Degeneration (AMD) Market Size and Share in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/agerelated-macular-degeneration-amd-market-size-and-trends-analysis-clinical-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast_557056.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-557056","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/557056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=557056"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/557056\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=557056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=557056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=557056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}